THBD and neoplasm: Concurrent integration of multi-omics data with emerging biomarkers—including circulating tumor DNA (ctDNA), microvesicles, and novel coagulation parameters (thrombin-antithrombin complex [TAT], plasmin-α2-plasmin inhibitor complex [PIC], thrombomodulin [TM], tissue plasminogen activator inhibitor complex [tPAI·C])—may substantially improve prognostic precision.